Quimatryx is devoted to the Discovery and Development of novel drugs against epigenetic targets focused on the area of cancer. Quimatryx Ltd has designed a best in class HDAC6 selective inhibitor, QTX125, with the aim of reducing the side effects of the treatment and beating the therapeutic activity of other HDAC inhibitors. The most advanced compounds have already shown a higher in vivo efficacy and safety profiles than the reference compounds, to treat pancreatic cancer and other invasive tumours.